Study on serum tRF-30-RRJ89O9NF5W8 as a potential biomarker for clinical diagnosis of gastric cancer.

IF 2.9 3区医学 Q2 ONCOLOGY

American journal of cancer research Pub Date : 2025-08-15 eCollection Date: 2025-01-01 DOI:10.62347/AIID7730

Zhihan Zhang, Chunyan Mao, Yi Wu, Yin Wang, Hui Cong

{"title":"Study on serum tRF-30-RRJ89O9NF5W8 as a potential biomarker for clinical diagnosis of gastric cancer.","authors":"Zhihan Zhang, Chunyan Mao, Yi Wu, Yin Wang, Hui Cong","doi":"10.62347/AIID7730","DOIUrl":null,"url":null,"abstract":"<p><p>Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. In this study, our objective was to identify a specific tRNA-derived small RNA (tsRNA) as a biomarker for GC. We developed and validated a methodology to detect the expression level of tRF-30-RRJ89O9NF5W8 in the serum of GC patients. The results showed that the expression of tRF-30-RRJ89O9NF5W8 was significantly downregulated in the serum of GC patients and increased after radical surgery. Clinicopathological correlation analysis revealed that its expression level was closely associated with TNM stage, T stage, and neural/vascular invasion. Compared with existing GC diagnostic markers, tRF-30-RRJ89O9NF5W8 demonstrated superior diagnostic performance, effectively distinguishing GC patients from those with gastritis and healthy controls. These findings suggest that tRF-30-RRJ89O9NF5W8 may serve as a promising candidate diagnostic biomarker for GC and provide theoretical support for its potential as a therapeutic target.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3486-3499"},"PeriodicalIF":2.9000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432573/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/AIID7730","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. In this study, our objective was to identify a specific tRNA-derived small RNA (tsRNA) as a biomarker for GC. We developed and validated a methodology to detect the expression level of tRF-30-RRJ89O9NF5W8 in the serum of GC patients. The results showed that the expression of tRF-30-RRJ89O9NF5W8 was significantly downregulated in the serum of GC patients and increased after radical surgery. Clinicopathological correlation analysis revealed that its expression level was closely associated with TNM stage, T stage, and neural/vascular invasion. Compared with existing GC diagnostic markers, tRF-30-RRJ89O9NF5W8 demonstrated superior diagnostic performance, effectively distinguishing GC patients from those with gastritis and healthy controls. These findings suggest that tRF-30-RRJ89O9NF5W8 may serve as a promising candidate diagnostic biomarker for GC and provide theoretical support for its potential as a therapeutic target.

查看原文本刊更多论文

血清tRF-30-RRJ89O9NF5W8作为胃癌临床诊断潜在生物标志物的研究

胃癌（GC）是全球癌症相关死亡的主要原因之一。在这项研究中，我们的目的是鉴定一种特定的trna衍生的小RNA （tsRNA）作为GC的生物标志物。我们开发并验证了一种检测GC患者血清中tRF-30-RRJ89O9NF5W8表达水平的方法。结果显示，胃癌患者血清中tRF-30-RRJ89O9NF5W8表达明显下调，根治性手术后表达升高。临床病理相关分析显示其表达水平与TNM分期、T分期及神经/血管浸润密切相关。与现有胃癌诊断标志物相比，tRF-30-RRJ89O9NF5W8具有更强的诊断效能，可有效区分胃癌患者与胃炎及健康对照者。这些发现表明，tRF-30-RRJ89O9NF5W8可能作为一种有希望的GC候选诊断生物标志物，并为其作为治疗靶点的潜力提供了理论支持。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of cancer research ONCOLOGY-

自引率

3.80%

发文量

263

期刊介绍： The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.